Should I buy or sell Alnylam Pharmaceuticals stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks .

What is Alnylam Pharmaceuticals' stock price target for 2024?

18 analysts have issued 1-year price targets for Alnylam Pharmaceuticals' shares. Their ALNY share price targets range from $161.00 to $395.00. On average, they predict the company's stock price to reach $216.12 in the next year. This suggests a possible upside of 46.3% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts .

How have ALNY shares performed in 2024?

Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of 2024. Since then, ALNY stock has decreased by 22.8% and is now trading at $147.70. View the best growth stocks for 2024 here .

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALNY earnings forecast .

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The biopharmaceutical company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the business earned ($1.68) earnings per share.

What ETFs hold Alnylam Pharmaceuticals' stock?

ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR) , Amplify Treatments, Testing and Advancements ETF (GERM) , Global X Genomics & Biotechnology ETF (GNOM) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , VanEck Biotech ETF (BBH) , Principal Healthcare Innovators ETF (BTEC) , Horizon Kinetics Medical ETF (MEDX) and American Century Focused Dynamic Growth ETF (FDG) .

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com . John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA) , NVIDIA (NVDA) , XOMA (XOMA) , Ionis Pharmaceuticals (IONS) , Gilead Sciences (GILD) , NXP Semiconductors (NXPI) , Mylan (MYL) , AbbVie (ABBV) , Micron Technology (MU) and Advanced Micro Devices (AMD) .

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Portman Square Capital LLP (0.00%), First Hawaiian Bank (0.00%) and Los Angeles Capital Management LLC (0.00%). Insiders that own company stock include Akshay Vaishnaw , Indrani Lall Franchini , Jeffrey V Poulton , Jeffrey W Dunn , John Maraganore , Laurie Keating , Michael W Bonney , Pushkal Garg , Steven M Paul , Tolga Tanguler and Yvonne Greenstreet . View institutional ownership trends .

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free ALNY Stock Alerts

$147.70

-0.80 (-0.54%)

(As of 04/15/2024 ET)

Compare

Today's Range: $146.73
▼
$150.37
50-Day Range: $146.51
▼
$172.18
52-Week Range: $143.52
▼
$218.88

Volume: 498,935 shs
Average Volume: 812,951 shs
Market Capitalization: $18.60 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $216.12

Get Alnylam Pharmaceuticals alerts:

Alnylam Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.56 Rating Score
Upside/Downside: 46.3% Upside
$216.12 Price Target
Short Interest: Healthy
2.22% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.52
Upright™ Environmental Score
News Sentiment: 0.66
Based on 17 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.54) to ($2.22) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.39 out of 5 stars

Medical Sector

98th out of 929 stocks

Pharmaceutical Preparations Industry

31st out of 422 stocks

4.3

Analyst's Opinion

Consensus Rating
Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 10 buy ratings, 8 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Alnylam Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
2.22% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Alnylam Pharmaceuticals has recently increased by 4.09%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Alnylam Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Alnylam Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Alnylam Pharmaceuticals is -1.52.

2.0

News and Social Media Coverage

News Sentiment
Alnylam Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for Alnylam Pharmaceuticals this week, compared to 9 articles on an average week.
Search Interest
Only 12 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders.
Percentage Held by Institutions
92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($4.54) to ($2.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alnylam Pharmaceuticals is -41.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alnylam Pharmaceuticals is -41.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALNY Stock News Headlines

April 13, 2024 | americanbankingnews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Buy by StockNews.com

April 13, 2024 | americanbankingnews.com

Zacks Research Comments on Alnylam Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:ALNY)

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

April 12, 2024 | americanbankingnews.com

Equities Analysts Set Expectations for Alnylam Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:ALNY)

April 11, 2024 | benzinga.com

Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking

April 9, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Alnylam Pharma on Strong Zilebesiran Trial Results and Lucrative Roche Partnership

April 9, 2024 | americanbankingnews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by William Blair

April 8, 2024 | msn.com

Wegovy Helps HFpEF Patients With Diabetes Mellitus

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

April 8, 2024 | msn.com

Study shows promise of zilebesiran injection in reducing systolic blood pressure

April 8, 2024 | markets.businessinsider.com

Jefferies Keeps Their Buy Rating on Alnylam Pharma (ALNY)

April 7, 2024 | markets.businessinsider.com

Alnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACC

April 7, 2024 | businesswire.com

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

April 7, 2024 | americanbankingnews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Lowered to Hold at StockNews.com

April 6, 2024 | finance.yahoo.com

Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%

April 5, 2024 | bizjournals.com

Alnylam CEO’s total pay nearly doubles, hitting $8.9M

April 3, 2024 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)

April 3, 2024 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)

April 2, 2024 | benzinga.com

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

March 26, 2024 | markets.businessinsider.com

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals

March 25, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Commercial Business and Expanding CNS Pipeline

March 20, 2024 | businesswire.com

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

March 19, 2024 | finance.yahoo.com

Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors

March 19, 2024 | markets.businessinsider.com

TD Cowen Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)

March 13, 2024 | businesswire.com

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

March 11, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

March 10, 2024 | seekingalpha.com

Is Alnylam's HELIOS-B Delay A Red Flag?

See More Headlines

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:ALNY
CUSIP: 02043Q10
CIK: 1178670
Web: www.alnylam.com
Phone: (617) 551-8200
Fax: 617-551-8101
Employees: 2,100
Year Founded: 2002

Price Target and Rating

Average Stock Price Target: $216.12
High Stock Price Target: $395.00
Low Stock Price Target: $161.00
Potential Upside/Downside: +46.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.56
Research Coverage: 18 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-440,240,000.00
Net Margins: -24.08%
Pretax Margin: -23.71%
Return on Equity: N/A
Return on Assets: -12.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.08
Quick Ratio: 2.99

Sales & Book Value

Annual Sales: $1.83 billion
Price / Sales: 10.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.76) per share
Price / Book: -83.92

Miscellaneous

Outstanding Shares: 125,946,000
Free Float: 124,057,000
Market Cap: $18.60 billion
Optionable: Optionable
Beta: 0.39

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Yvonne L. Greenstreet M.B.A. (Age 61)
MBChB, CEO & Director
Comp: $2.09M
Mr. Jeffrey V. Poulton M.B.A. (Age 56)
CFO & Executive VP
Comp: $972.35k
Dr. Akshay K. Vaishnaw M.D. (Age 61)
Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board
Comp: $1.24M
Dr. Pushkal P. Garg M.D. (Age 56)
Chief Medical Officer and Executive VP of Development & Medical Affairs
Comp: $1M
Mr. Timothy J. Maines
Chief Technical Operations & Quality Officer
Dr. Kevin Joseph Fitzgerald Ph.D. (Age 55)
Senior VP, Head of Research & Chief Scientific Officer
Ms. Christine Regan Lindenboom (Age 43)
Senior VP of Investor Relations & Corporate Communications
Mr. Piyush Sharma J.D.
Chief Ethics & Compliance Officer
Mr. Evan Lippman
Chief Corporate Development & Strategy Officer
Ms. Kelley Boucher
Chief Human Resource Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

Alnylam Pharmaceuticals has a diverse portfolio of innovative therapeutics based on ribonucleic acid interference, including successful products like ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, targeting various rare diseases.
The company has shown consistent revenue growth, with a 31.2% increase in revenue year-over-year, indicating a strong market presence and potential for further expansion.
Recent earnings reports have shown positive results, with the company beating consensus estimates and demonstrating resilience in challenging market conditions.
Institutional investors have been increasing their stakes in Alnylam Pharmaceuticals, signaling confidence in the company's future prospects and growth potential.
Alnylam Pharmaceuticals' stock has a low beta of 0.39, indicating lower volatility compared to the market, which can be attractive to risk-averse investors.

Cons

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring new products to market and maintain profitability.
Alnylam Pharmaceuticals' stock price may be influenced by factors such as clinical trial results, regulatory approvals, and market sentiment, leading to potential short-term volatility.
Investing in biotechnology companies like Alnylam Pharmaceuticals carries inherent risks related to product development, clinical trial outcomes, and market acceptance, which can lead to significant fluctuations in stock value.
The company's future success heavily relies on the continued innovation and commercialization of its pipeline products, which may face delays or setbacks in development, impacting financial performance.
Market conditions and macroeconomic factors can also affect the biopharmaceutical sector, potentially impacting Alnylam Pharmaceuticals' stock performance and overall investor returns.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

ALNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.
What is Alnylam Pharmaceuticals' stock price target for 2024?: 18 analysts have issued 1-year price targets for Alnylam Pharmaceuticals' shares. Their ALNY share price targets range from $161.00 to $395.00. On average, they predict the company's stock price to reach $216.12 in the next year. This suggests a possible upside of 46.3% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.
How have ALNY shares performed in 2024?: Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of 2024. Since then, ALNY stock has decreased by 22.8% and is now trading at $147.70.
View the best growth stocks for 2024 here.
When is Alnylam Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALNY earnings forecast.
How were Alnylam Pharmaceuticals' earnings last quarter?: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The biopharmaceutical company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the business earned ($1.68) earnings per share.
What ETFs hold Alnylam Pharmaceuticals' stock?: ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Principal Healthcare Innovators ETF (BTEC), Horizon Kinetics Medical ETF (MEDX) and American Century Focused Dynamic Growth ETF (FDG).

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?: Alnylam Pharmaceuticals updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.
What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?: 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Alnylam Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).
Who are Alnylam Pharmaceuticals' major shareholders?: Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Portman Square Capital LLP (0.00%), First Hawaiian Bank (0.00%) and Los Angeles Capital Management LLC (0.00%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends.
How do I buy shares of Alnylam Pharmaceuticals?: Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALNY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial